Company Overview
Jyong Biotech Ltd. operates as a science-driven biotechnology entity focused on the development and commercialization of plant-derived pharmaceuticals designed to treat urinary system diseases across the United States, the European Union, and Asia. Within the broader healthcare sector, the company specifically functions within the biotechnology industry, distinguishing itself through its specialized pursuit of medical solutions for conditions such as benign prostate hyperplasia and lower urinary tract symptoms using its MCS-2 therapeutic candidate. The company currently maintains a market capitalization of $158.90M, while specific figures regarding annual revenue and employee count are not disclosed in the available data. These valuation metrics place the firm in the category of a mid-sized biotechnology enterprise, suggesting a capitalization level that reflects the high-risk, high-reward profile typical of companies in the early to mid-stages of product development and commercialization cycles.
Financial Health
The company's financial performance over the trailing twelve months is characterized by a net income loss of $-2,945,000 and an EBITDA of $-1,803,000, while revenue data is currently unavailable. The absence of reported revenue figures combined with significant net losses indicates a cost structure where operating expenses, likely driven by research and development activities, substantially exceed any current income generated from sales. Free cash flow is not available for analysis, which limits the ability to assess the company's immediate financial flexibility or its capacity to fund operations without external capital injections. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, a status typical for biotechnology firms that have not yet achieved commercial sales or where current revenues are insufficient to cover the cost of goods sold. The balance sheet shows a cash position of $17.01M against total debt of $35.19M, resulting in a negative debt-to-equity ratio of -6.68 which suggests a highly leveraged financial structure where liabilities exceed equity. Although the company holds significant cash reserves, the current ratio stands at 0.62, indicating that current assets are less than half of current liabilities and signaling potential short-term liquidity challenges. Return on assets is -5.4%, revealing that the company's assets are generating negative returns, while return on equity is not available due to the company's negative equity position.
Valuation Assessment
Trailing and forward P/E ratios are both unavailable, a common characteristic for biotechnology companies that are currently unprofitable and therefore do not generate earnings per share suitable for traditional multiple analysis. The price-to-book ratio is -6.68, which indicates that the market values the company at a significant premium over its book value, a situation often driven by the intangible value of intellectual property and pipeline potential rather than current tangible assets. Price-to-sales ratio and EV/EBITDA multiples are reported as -93.27 and unavailable respectively, suggesting that alternative valuation metrics are skewed by the company's negative earnings and lack of historical sales data. The stock has experienced extreme volatility, trading between a 52-week low of $1.43 and a 52-week high of $67.00, with the current share price situated at a level that reflects the wide disparity between the asset's recent performance peaks and troughs. Beta is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market index.
Growth & Income
Revenue growth and earnings growth rates are both unavailable, preventing a direct comparison of the pace at which earnings are growing relative to revenue. Given that the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the firm retains all available earnings to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. The company's financial profile is defined by a total absence of current dividend income, which aligns with its strategy of prioritizing growth through asset accumulation and pipeline advancement over shareholder payouts. The overall growth and income profile is currently characterized by a reliance on future product milestones rather than established historical growth rates or current dividend yields.